Biotech, FDA, Life Sciences Luke Timmerman wrote: Genzyme got some bad news today from the FDA. The Cambridge, MA-based biotech company said that U.S. regulators determined its drug for Pompe disease made in large-scale vats isn’t ready to be approved for the market. Plus, the FDA sent the com...

There are a number of interesting cancer drugs in development that may receive approval this year.  Many of them are from biotech rather than pharma and focused on niche indications. First up is Genzyme's Clolar (clofarabine), which was filed as a supplemental application in the US on November 24th...

Biotech, cancer, deals Luke Timmerman wrote: The recession will surely kill off some biotech companies that lack hard cash and the hard data that shows their experimental drugs can improve patients’ lives. But after I heard Seattle Genetics CEO Clay Siegall tell the story of how his company ra...

Biotech, Devices, people Luke Timmerman wrote: Washington state’s life sciences trade group has a new boss, Chris Rivera, who has made a career in the high-pressure world of sales and marketing of new biotech drugs. Rivera’s new challenge, starting this month, is to help strengthen this ...

Biotech, Cash, Life Sciences Luke Timmerman wrote: Boston is the biggest center of life sciences in the Xconomy network, and by our analysis, the Bay State’s biotech sector is also the best equipped to survive the economic crisis. I reached this conclusion by combing through public company fil...

Biotech, Multiple Sclerosis, Drugs Luke Timmerman wrote: If Genzyme gets its way, it will be eating Biogen Idec’s lunch in a few more years. The two Cambridge, MA-based companies, the largest independent biotechs in the state, could be duking it out with competing multiple sclerosis treatments...